NZ528624A - Antibodies against cancer - Google Patents

Antibodies against cancer

Info

Publication number
NZ528624A
NZ528624A NZ528624A NZ52862402A NZ528624A NZ 528624 A NZ528624 A NZ 528624A NZ 528624 A NZ528624 A NZ 528624A NZ 52862402 A NZ52862402 A NZ 52862402A NZ 528624 A NZ528624 A NZ 528624A
Authority
NZ
New Zealand
Prior art keywords
antibody
cancer
fragment
monoclonal
antibodies against
Prior art date
Application number
NZ528624A
Other languages
English (en)
Inventor
Ian Farquar Campbell Mckenzie
Pei-Xiang Xing
Original Assignee
Austin Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Austin Research Inst filed Critical Austin Research Inst
Publication of NZ528624A publication Critical patent/NZ528624A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ528624A 2001-03-26 2002-03-26 Antibodies against cancer NZ528624A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR3958A AUPR395801A0 (en) 2001-03-26 2001-03-26 Antibodies against cancer
PCT/AU2002/000362 WO2002077033A1 (en) 2001-03-26 2002-03-26 Antibodies against cancer

Publications (1)

Publication Number Publication Date
NZ528624A true NZ528624A (en) 2006-03-31

Family

ID=3827964

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ528624A NZ528624A (en) 2001-03-26 2002-03-26 Antibodies against cancer

Country Status (9)

Country Link
US (1) US7318924B2 (enExample)
EP (1) EP1383801A4 (enExample)
JP (2) JP4854912B2 (enExample)
KR (1) KR100909290B1 (enExample)
CN (2) CN101310770A (enExample)
AU (3) AUPR395801A0 (enExample)
CA (1) CA2442318A1 (enExample)
NZ (1) NZ528624A (enExample)
WO (1) WO2002077033A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
HUP0501113A3 (en) * 2001-04-26 2007-12-28 Biogen Idec Inc Cripto blocking antibodies and uses thereof
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
CA2502681A1 (en) * 2002-10-23 2004-05-06 Exelixis, Inc. Mbms as modifiers of branching morphogenesis and methods of use
WO2004090158A1 (ja) * 2003-04-03 2004-10-21 Oncorex, Inc. 医薬品
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
US7820620B2 (en) * 2003-09-15 2010-10-26 Research Development Foundation Cripto antagonism of activin and TGF-b signaling
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
EP2311880A3 (en) * 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto binding molecules
US7939056B2 (en) * 2005-11-14 2011-05-10 The Brigham And Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
CA2688563A1 (en) * 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
CA2728739C (en) 2008-06-20 2017-07-11 Duke University Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
KR100973029B1 (ko) * 2008-10-07 2010-08-11 박지운 알루미늄 합금 가로등 등주
JP5805538B2 (ja) * 2008-11-07 2015-11-04 リサーチ ディベロップメント ファウンデーション Ｃｒｉｐｔｏ／ＧＳＰ７８複合体形成およびシグナル伝達を阻害するための組成物および方法
WO2012105219A1 (ja) * 2011-01-31 2012-08-09 オリンパス株式会社 抗体療法の効果増強剤
AU2012244673A1 (en) 2011-04-21 2013-11-28 Seattle Genetics, Inc. Novel binder-drug conjugates (ADCs) and their use
CN106163568B (zh) 2013-12-23 2021-03-23 拜耳制药股份公司 含纺锤体驱动蛋白（ksp）的抗体药物偶联物（adc）
CA2983311A1 (en) * 2015-04-20 2016-10-27 Minomic International Ltd. Therapeutic antibodies and uses thereof
EP3310440A1 (de) 2015-06-22 2018-04-25 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
HK1246717A1 (zh) 2015-06-23 2018-09-14 Bayer Pharma Aktiengesellschaft Ksp抑制剂的靶向缀合物
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
JP7022707B2 (ja) 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ）
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
PE20191235A1 (es) 2016-12-21 2019-09-11 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
CN109744199A (zh) * 2017-11-08 2019-05-14 南京艾莫瑞生物科技有限公司 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用
JP6761889B1 (ja) * 2019-11-11 2020-09-30 株式会社Ｇｓｐエンタープライズ 抗ヒトＣｒｉｐｔｏ−１抗体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US5256643A (en) * 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5264557A (en) * 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
KR20000015893A (ko) 1996-05-22 2000-03-15 댄 마이클 특이적으로 암세포를 검출하는 항원 결합 단편, 상기 단편을 코딩하는 뉴클레오티드 및 암의 예방 및 검출에 사용되는 이들의 용도
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
ID29246A (id) * 1999-03-11 2001-08-16 Ardenia Investments Ltd Senyawa-senyawa baru untuk pengobatan kanker
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
WO2002022808A2 (en) 2000-09-18 2002-03-21 Biogen, Inc. Cripto mutant and uses thereof
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
HUP0501113A3 (en) 2001-04-26 2007-12-28 Biogen Idec Inc Cripto blocking antibodies and uses thereof

Also Published As

Publication number Publication date
EP1383801A1 (en) 2004-01-28
US7318924B2 (en) 2008-01-15
WO2002077033A1 (en) 2002-10-03
EP1383801A4 (en) 2005-06-01
CN100457781C (zh) 2009-02-04
CN1639194A (zh) 2005-07-13
AUPR395801A0 (en) 2001-04-26
CN101310770A (zh) 2008-11-26
JP4854912B2 (ja) 2012-01-18
JP2004534741A (ja) 2004-11-18
CA2442318A1 (en) 2002-10-03
KR20040010613A (ko) 2004-01-31
JP2009024014A (ja) 2009-02-05
AU2007201587A1 (en) 2007-05-03
AU2002240719B2 (en) 2007-01-11
US20040176576A1 (en) 2004-09-09
KR100909290B1 (ko) 2009-07-24

Similar Documents

Publication Publication Date Title
NZ528624A (en) Antibodies against cancer
RU2008128244A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
IL161686A (en) Use of a soluble monoclonal antibody that specifically binds trail receptor dr5 in the manufacture of pharmaceutical compositions targeting cells expressing dr5
JP2003503361A5 (enExample)
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2004032857A3 (en) Antibody therapy
JP2004534741A5 (enExample)
WO2004010947A3 (en) Humanized antibodies against human 4-1bb
ZA200609407B (en) Monoclonal antibodies to hepatocyte growth factor
NZ568769A (en) Human monoclonal antibodies against CD20
UA89350C2 (uk) Гуманізоване антитіло, що зв'язує людський cd20
GEP20104998B (en) Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
NZ596878A (en) Methods of administering anti-tnfalpha antibodies
WO2003099196A3 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
TR200102845T2 (tr) Kanserlerin iyileştirilmesi için RHUMAB HER2 ile birlikte dosetaksel
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
EP4219556A3 (en) Human monoclonal antibodies specific for flt3 and uses thereof
TW200517124A (en) Fully human antibodies against human 4-1BB
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
WO2024062072A3 (en) Anti-ccr8 monoclonal antibodies and their therapeutic use
PL1684770T3 (pl) Oligo-beta-(1,3)-glukan i przeciwrakowe przeciwciała monoklonalne
EP2641611A3 (en) Combination therapy

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed